skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Aritibe came out with a report, I believe today, with a sale of one of their drugs. Sale takes place over 3 years, I believe. I see the market took no notice of this, but I'm wondering what your opinion is.

UGE had a Q report, last week, the stock has gone down, so I assume the market was not impressed. What is your opinion.

NDVA the company appears to be doing very well, so again please comment.

I did check the investment questions, but none of these companies have been touched on in some time.

Thank you for your good work.
Earl


Read Answer Asked by Earl on May 06, 2022
Q: This pharma. comp. recently had studies, showing positive results when linking a base drug to its hydrogen sulfide releasing molecule . so that the drug would be easier on the body when taken. Yet the stock went down from its high of $0.80 ( plus ) to the now price $ 0.42. Appreciate any comments you may have on this company and what the future might hold for the technique they are developing . Thanks
Read Answer Asked by Frank on July 21, 2020
Q: The recent fall in the share price appears to be the result of the share issue at 0.40, which is well off the market price prior to the issue. So the market got this wrong? Or am I missing something? While phase iii tests appear to be lengthy the commentary was that at this stage risk is much reduced; and other bioT's entering phase iii tests do not seem to suffer as much; and I see no competitor(s) offering comparable benefits. Becoming more concerned than puzzled.
Read Answer Asked by Mike on July 13, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!